AZD1152 in Patients With Advanced Solid Malignancies-Study 3
Phase 1
Terminated
- Conditions
- Solid Tumours
- Registration Number
- NCT00497679
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
- Histological or cytological confirmation of a solid, malignant tumour
Exclusion Criteria
- Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
- Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
- Recent major surgery within 4 weeks prior to entry to the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety and Tolerability Assessed at each visit
- Secondary Outcome Measures
Name Time Method Pharmacokinetics Assessed at predetermined timepoints after dose administration Effect on biomarkers Assessed after treatment Anti-tumor activity Assessed at the end of treatment
Trial Locations
- Locations (1)
Research Site
🇬🇧Oxford, United Kingdom